141.35
+0.68(+0.48%)
Currency In USD
| Previous Close | 140.67 |
| Open | 139.89 |
| Day High | 143.23 |
| Day Low | 137.2 |
| 52-Week High | 204.18 |
| 52-Week Low | 110.04 |
| Volume | 1.62M |
| Average Volume | 1.41M |
| Market Cap | 20.72B |
| PE | 13.53 |
| EPS | 10.45 |
| Moving Average 50 Days | 132.71 |
| Moving Average 200 Days | 136.66 |
| Change | 0.68 |
If you invested $1000 in Biogen Inc. (BIIB) 10 years ago, it would be worth $465.76 as of September 09, 2025 at a share price of $141.35. Whereas If you bought $1000 worth of Biogen Inc. (BIIB) shares 5 years ago, it would be worth $518.7 as of September 09, 2025 at a share price of $141.35.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
GlobeNewswire Inc.
Sep 02, 2025 11:00 AM GMT
– Durable reductions in seizures and continuing improvements in cognition and behavior through 3 years in patients who continued to receive zorevunersen in the open-label extension studies – – Substantial increase in seizure-free days and continuous
Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
GlobeNewswire Inc.
Aug 25, 2025 11:00 AM GMT
– 3-year data from open-label extension (OLE) studies demonstrate the potential for disease modification with durable seizure reductions and improvements in cognition and behavior on top of standard anti-seizure medicines – – Substantial improvement
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)
GlobeNewswire Inc.
Aug 25, 2025 7:00 AM GMT
TOKYO and CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”